Energy PeptidesResearch grade

NAD+

Price range: CA$92.99 through CA$141.99

Lyophilized powder (unreconstituted)

Laboratory tested Verified purity and identity
Tracked regional shipping Free shipping when eligible
Secure payment Available methods shown at checkout

For laboratory and research purposes only. Not intended for human use, diagnosis or treatment.

NAD+

NAD+ is supplied for laboratory research workflows that require clear product identity, careful handling, and documented specifications.

Research use only. Not for human or veterinary consumption, diagnosis, or treatment.

Weight 0.050 lbs
Quantity

500 mg, 1000 mg

📊 Research Dosages and Protocols

Research phase Research dosage Administration frequency
Starting / Adaptation 50 mg 1-2 times weekly
Primary / Maintenance 100 - 200 mg 2-3 times weekly
Maximum exposure 500 mg Daily (depending on the model)

* Note: The listed dosages are based on reference research models and should be adapted to the specific requirements of your laboratory protocol.

🧫 Reconstitution and Storage

  • Reconstitution: Bacteriostatic Water (BAC Water) is recommended. Add it slowly down the side of the vial. Gently swirl the vial without shaking aggressively.
  • Storage (lyophilized powder): Store in a dark place at -20°C to 4°C.
  • Storage (reconstituted): After reconstitution, refrigerate at 2°C to 8°C and use within 20–30 days.

🔬 Observed Research Findings

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism:

  • Cellular energy: Research links NAD+ availability with mitochondrial function and ATP production.
  • Metabolism: Human studies have explored effects on insulin sensitivity and healthy aging.
  • Neuroprotection: It is being investigated for potential protection against oxidative stress in neural cells.

* Sold for laboratory research and in vitro models only. The information above summarizes findings reported in published medical literature and human clinical studies.

Frequently asked questions will be added before launch.

Research articles

View all articles